CRDL Stock Analysis: Buy, Sell, or Hold?
CRDL - Cardiol Therapeutics Inc. Class A Common Shares
$2.00
0.02 (0.76%)
â˛
5d:
-7.64%
30d:
+31.25%
90d:
+86.45%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When CRDL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CRDL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CRDL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CRDL is currently trading at $2.00, which is considered slightly high relative to its 30-day fair value range of $1.54 to $2.14.
Technical Outlook: Technically, CRDL is in a uptrend. Immediate support is located at $1.88, while resistance sits at $2.34.
Market Sentiment: CRDL scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.53 (+327.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRDL is in a uptrend. Immediate support is located at $1.88, while resistance sits at $2.34.
Market Sentiment: CRDL scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.53 (+327.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.54 -
$2.14
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 327.5% below Wall St target ($8.53)
- WARNING: Composite score 33/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.54 -
$2.14
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.88
Resistance Level
$2.34
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.01
Wall Street Target
$8.53
(+327.5%)
Share & Embed Analysis
Last updated: September 12, 2026 7:11 AM ET
Data refreshes hourly during market hours. Next update: 8:11 AM
Data refreshes hourly during market hours. Next update: 8:11 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRDL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary ShâĻ |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
